Posted by Michael Wonder on 24 Jul 2023
ViiV Healthcare’s cabotegravir for HIV prevention receives positive CHMP opinion from European Medicines Agency
24 July 2023 - Positive opinion is based on results from the HPTN 083 and 084 Phase IIb/III studies in which the medicine, given as few as six times per year, demonstrated superior efficacy to a daily oral PrEP option in reducing the risk of HIV acquisition.
GSK announced that ViiV Healthcare welcomed a positive opinion by the EMA's CHMP recommending marketing authorisation for cabotegravir long-acting injectable and tablets for HIV prevention.
